UA78529C2 - Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain - Google Patents

Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain Download PDF

Info

Publication number: UA78529C2
Authority: UA; Ukraine
Prior art keywords: pain; dioxo; carbon atoms; diazabicyclo; formula
Prior art date: 2001-10-10

Application number

UA20040503402A

Other languages

English (en)

Ukrainian (uk)

Inventor

Michael Richard Brandt

Margaret Maria Zaleska

John Allen Moyer

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-10

Filing date

2002-09-10

Publication date

2007-04-10

2002-09-10 Application filed by Wyeth Corp filed Critical Wyeth Corp

2007-04-10 Publication of UA78529C2 publication Critical patent/UA78529C2/uk

Links

208000002193 Pain Diseases 0.000 title claims abstract description 155
230000036407 pain Effects 0.000 title claims abstract description 119
125000000217 alkyl group Chemical group 0.000 title claims abstract description 45
125000002924 primary amino group Chemical group [H]N([H])* 0.000 title claims description 11
239000002253 acid Substances 0.000 title claims description 8
150000001875 compounds Chemical class 0.000 claims abstract description 89
238000000034 method Methods 0.000 claims abstract description 46
238000011282 treatment Methods 0.000 claims abstract description 43
-1 5-tetrazolyl Chemical group 0.000 claims abstract description 35
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
241000124008 Mammalia Species 0.000 claims abstract description 21
125000002947 alkylene group Chemical group 0.000 claims abstract description 16
125000003884 phenylalkyl group Chemical group 0.000 claims abstract description 12
125000004450 alkenylene group Chemical group 0.000 claims abstract description 11
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 10
125000003342 alkenyl group Chemical group 0.000 claims abstract description 7
125000004432 carbon atom Chemical group C* 0.000 claims description 69
229910052739 hydrogen Inorganic materials 0.000 claims description 42
239000001257 hydrogen Substances 0.000 claims description 42
239000003795 chemical substances by application Substances 0.000 claims description 40
150000003839 salts Chemical class 0.000 claims description 33
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 26
150000002431 hydrogen Chemical group 0.000 claims description 24
239000000203 mixture Substances 0.000 claims description 20
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
208000004296 neuralgia Diseases 0.000 claims description 16
208000021722 neuropathic pain Diseases 0.000 claims description 16
208000000094 Chronic Pain Diseases 0.000 claims description 14
230000006378 damage Effects 0.000 claims description 14
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 11
239000000014 opioid analgesic Substances 0.000 claims description 11
238000001356 surgical procedure Methods 0.000 claims description 10
239000000730 antalgic agent Substances 0.000 claims description 9
239000002775 capsule Substances 0.000 claims description 9
206010019233 Headaches Diseases 0.000 claims description 8
208000004454 Hyperalgesia Diseases 0.000 claims description 8
239000002552 dosage form Substances 0.000 claims description 8
231100000869 headache Toxicity 0.000 claims description 8
206010028980 Neoplasm Diseases 0.000 claims description 7
102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 claims description 7
101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 claims description 7
208000027418 Wounds and injury Diseases 0.000 claims description 7
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
101150047356 dec-1 gene Proteins 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
208000014674 injury Diseases 0.000 claims description 7
206010058019 Cancer Pain Diseases 0.000 claims description 6
206010061218 Inflammation Diseases 0.000 claims description 6
229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
239000002260 anti-inflammatory agent Substances 0.000 claims description 6
229940079593 drug Drugs 0.000 claims description 6
230000004054 inflammatory process Effects 0.000 claims description 6
208000009935 visceral pain Diseases 0.000 claims description 6
208000008035 Back Pain Diseases 0.000 claims description 5
206010006002 Bone pain Diseases 0.000 claims description 5
206010064012 Central pain syndrome Diseases 0.000 claims description 5
206010065390 Inflammatory pain Diseases 0.000 claims description 5
206010028391 Musculoskeletal Pain Diseases 0.000 claims description 5
201000011510 cancer Diseases 0.000 claims description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
125000005499 phosphonyl group Chemical group 0.000 claims description 5
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
208000035154 Hyperesthesia Diseases 0.000 claims description 4
206010053552 allodynia Diseases 0.000 claims description 4
229940035676 analgesics Drugs 0.000 claims description 4
239000001961 anticonvulsive agent Substances 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 3
208000001640 Fibromyalgia Diseases 0.000 claims description 3
208000002720 Malnutrition Diseases 0.000 claims description 3
208000019695 Migraine disease Diseases 0.000 claims description 3
208000001294 Nociceptive Pain Diseases 0.000 claims description 3
206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
206010037779 Radiculopathy Diseases 0.000 claims description 3
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 3
229940123445 Tricyclic antidepressant Drugs 0.000 claims description 3
208000005298 acute pain Diseases 0.000 claims description 3
239000003053 toxin Substances 0.000 claims description 3
231100000765 toxin Toxicity 0.000 claims description 3
108700012359 toxins Proteins 0.000 claims description 3
239000003029 tricyclic antidepressant agent Substances 0.000 claims description 3
208000023275 Autoimmune disease Diseases 0.000 claims description 2
208000035143 Bacterial infection Diseases 0.000 claims description 2
208000018380 Chemical injury Diseases 0.000 claims description 2
208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims description 2
206010050219 Lumbar radiculopathy Diseases 0.000 claims description 2
206010028836 Neck pain Diseases 0.000 claims description 2
208000004983 Phantom Limb Diseases 0.000 claims description 2
206010056238 Phantom pain Diseases 0.000 claims description 2
208000036142 Viral infection Diseases 0.000 claims description 2
239000000556 agonist Substances 0.000 claims description 2
208000022362 bacterial infectious disease Diseases 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
201000005442 glossopharyngeal neuralgia Diseases 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
210000005036 nerve Anatomy 0.000 claims description 2
239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 2
235000018343 nutrient deficiency Nutrition 0.000 claims description 2
208000033808 peripheral neuropathy Diseases 0.000 claims description 2
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 2
239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 2
208000007056 sickle cell anemia Diseases 0.000 claims description 2
208000012720 thalamic disease Diseases 0.000 claims description 2
206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
230000003612 virological effect Effects 0.000 claims description 2
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 25
125000004429 atom Chemical group 0.000 claims 3
229910052799 carbon Inorganic materials 0.000 claims 2
GRKSQRAVWODMGW-UHFFFAOYSA-N ethylphosphonic acid Chemical compound [CH2]CP(O)(O)=O GRKSQRAVWODMGW-UHFFFAOYSA-N 0.000 claims 2
238000004806 packaging method and process Methods 0.000 claims 2
206010050217 Cervical radiculopathy Diseases 0.000 claims 1
230000003556 anti-epileptic effect Effects 0.000 claims 1
229960003965 antiepileptics Drugs 0.000 claims 1
239000003638 chemical reducing agent Substances 0.000 claims 1
206010027599 migraine Diseases 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 42
125000001047 cyclobutenyl group Chemical class C1(=CCC1)* 0.000 description 41
206010020751 Hypersensitivity Diseases 0.000 description 29
208000026935 allergic disease Diseases 0.000 description 29
230000009610 hypersensitivity Effects 0.000 description 29
230000000694 effects Effects 0.000 description 23
229960005181 morphine Drugs 0.000 description 20
108020003175 receptors Proteins 0.000 description 19
238000012360 testing method Methods 0.000 description 19
239000005557 antagonist Substances 0.000 description 17
239000002464 receptor antagonist Substances 0.000 description 17
229940044551 receptor antagonist Drugs 0.000 description 17
239000003826 tablet Substances 0.000 description 16
241000700159 Rattus Species 0.000 description 13
108091006146 Channels Proteins 0.000 description 12
229960004640 memantine Drugs 0.000 description 12
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 12
XNQULTQRGBXLIA-UHFFFAOYSA-O phosphonic anhydride Chemical compound O[P+](O)=O XNQULTQRGBXLIA-UHFFFAOYSA-O 0.000 description 12
230000004044 response Effects 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
239000007788 liquid Substances 0.000 description 11
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 10
229960003299 ketamine Drugs 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
229930195712 glutamate Natural products 0.000 description 8
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 8
238000010998 test method Methods 0.000 description 8
LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 7
230000002093 peripheral effect Effects 0.000 description 7
239000007787 solid Substances 0.000 description 7
206010003591 Ataxia Diseases 0.000 description 6
102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 6
229940126062 Compound A Drugs 0.000 description 6
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
239000000969 carrier Substances 0.000 description 6
230000001684 chronic effect Effects 0.000 description 6
230000002860 competitive effect Effects 0.000 description 6
229950004794 dizocilpine Drugs 0.000 description 6
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
230000002385 psychotomimetic effect Effects 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
230000002277 temperature effect Effects 0.000 description 6
206010039897 Sedation Diseases 0.000 description 5
230000000052 comparative effect Effects 0.000 description 5
230000006835 compression Effects 0.000 description 5
238000007906 compression Methods 0.000 description 5
206010039073 rheumatoid arthritis Diseases 0.000 description 5
230000036280 sedation Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
230000008542 thermal sensitivity Effects 0.000 description 5
UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 4
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
239000004471 Glycine Substances 0.000 description 4
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 4
229960001138 acetylsalicylic acid Drugs 0.000 description 4
239000013543 active substance Substances 0.000 description 4
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 4
229960003805 amantadine Drugs 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
229960001985 dextromethorphan Drugs 0.000 description 4
239000000945 filler Substances 0.000 description 4
229960003998 ifenprodil Drugs 0.000 description 4
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
229920000768 polyamine Polymers 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000012549 training Methods 0.000 description 4
229940122459 Glutamate antagonist Drugs 0.000 description 3
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
230000002411 adverse Effects 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
229960001680 ibuprofen Drugs 0.000 description 3
239000012535 impurity Substances 0.000 description 3
229960000905 indomethacin Drugs 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
208000028867 ischemia Diseases 0.000 description 3
229960002009 naproxen Drugs 0.000 description 3
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
230000003533 narcotic effect Effects 0.000 description 3
230000036963 noncompetitive effect Effects 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
201000008482 osteoarthritis Diseases 0.000 description 3
230000036285 pathological change Effects 0.000 description 3
231100000915 pathological change Toxicity 0.000 description 3
230000002085 persistent effect Effects 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
210000003497 sciatic nerve Anatomy 0.000 description 3
239000002904 solvent Substances 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
239000000375 suspending agent Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
210000003934 vacuole Anatomy 0.000 description 3
230000002477 vacuolizing effect Effects 0.000 description 3
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
208000007514 Herpes zoster Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
208000008930 Low Back Pain Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000028389 Nerve injury Diseases 0.000 description 2
206010033645 Pancreatitis Diseases 0.000 description 2
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
208000004550 Postoperative Pain Diseases 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
206010070834 Sensitisation Diseases 0.000 description 2
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
239000003194 amino acid receptor blocking agent Substances 0.000 description 2
229960000836 amitriptyline Drugs 0.000 description 2
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
239000002876 beta blocker Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229960000623 carbamazepine Drugs 0.000 description 2
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
229960000590 celecoxib Drugs 0.000 description 2
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
229960004126 codeine Drugs 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
229960003914 desipramine Drugs 0.000 description 2
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
229960001193 diclofenac sodium Drugs 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
208000002173 dizziness Diseases 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
235000013305 food Nutrition 0.000 description 2
229960002870 gabapentin Drugs 0.000 description 2
229960003132 halothane Drugs 0.000 description 2
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 2
229960001410 hydromorphone Drugs 0.000 description 2
229960004801 imipramine Drugs 0.000 description 2
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
229960000991 ketoprofen Drugs 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
230000005906 menstruation Effects 0.000 description 2
239000002756 mu opiate receptor agonist Substances 0.000 description 2
239000004084 narcotic analgesic agent Substances 0.000 description 2
230000008764 nerve damage Effects 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
229940005483 opioid analgesics Drugs 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229960005489 paracetamol Drugs 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
229960001639 penicillamine Drugs 0.000 description 2
210000001428 peripheral nervous system Anatomy 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229950010883 phencyclidine Drugs 0.000 description 2
229960002036 phenytoin Drugs 0.000 description 2
229960002702 piroxicam Drugs 0.000 description 2
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
239000011591 potassium Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
229960000371 rofecoxib Drugs 0.000 description 2
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
230000008313 sensitization Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
229940084026 sodium valproate Drugs 0.000 description 2
JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000001629 suppression Effects 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
230000036962 time dependent Effects 0.000 description 2
229960004394 topiramate Drugs 0.000 description 2
230000008736 traumatic injury Effects 0.000 description 2
210000001835 viscera Anatomy 0.000 description 2
230000009278 visceral effect Effects 0.000 description 2
LPMRCCNDNGONCD-NTSWFWBYSA-N (2r,4s)-4-(phosphonomethyl)piperidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1 LPMRCCNDNGONCD-NTSWFWBYSA-N 0.000 description 1
RXYPXQSKLGGKOL-UHFFFAOYSA-O 1,4-dimethylpiperazin-1-ium Chemical compound CN1CC[NH+](C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-O 0.000 description 1
BPWDIXPFAHESAF-UHFFFAOYSA-N 1-[3,3-dimethyl-5-(4-methylsulfonylphenyl)cyclopenta-1,4-dien-1-yl]-4-fluorobenzene Chemical compound C=1C(C)(C)C=C(C=2C=CC(F)=CC=2)C=1C1=CC=C(S(C)(=O)=O)C=C1 BPWDIXPFAHESAF-UHFFFAOYSA-N 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
AXWLKJWVMMAXBD-UHFFFAOYSA-N 1-butylpiperidine Chemical compound CCCCN1CCCCC1 AXWLKJWVMMAXBD-UHFFFAOYSA-N 0.000 description 1
PAMIQIKDUOTOBW-UHFFFAOYSA-O 1-methylpiperidin-1-ium Chemical compound C[NH+]1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-O 0.000 description 1
ZAVJTSLIGAGALR-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclooctan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCCCC1=O ZAVJTSLIGAGALR-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
RPTFKXDBRBKHQU-UHFFFAOYSA-N 4-(2-oxo-3-phenyl-1,3-oxazol-4-yl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=COC(=O)N1C1=CC=CC=C1 RPTFKXDBRBKHQU-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
206010000050 Abdominal adhesions Diseases 0.000 description 1
206010000234 Abortion spontaneous Diseases 0.000 description 1
208000005641 Adenomyosis Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
101100155017 Arabidopsis thaliana RCE2 gene Proteins 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
206010005052 Bladder irritation Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
108091005462 Cation channels Proteins 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
206010013954 Dysphoria Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
208000009774 Follicular Cyst Diseases 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
206010061296 Motor dysfunction Diseases 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
206010028347 Muscle twitching Diseases 0.000 description 1
208000030858 Myofascial Pain Syndromes Diseases 0.000 description 1
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
206010033119 Ovarian abscess Diseases 0.000 description 1
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
108010063843 Phencyclidine Receptors Proteins 0.000 description 1
NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-O Pyrrolidinium ion Chemical compound C1CC[NH2+]C1 RWRDLPDLKQPQOW-UHFFFAOYSA-O 0.000 description 1
LPMRCCNDNGONCD-RITPCOANSA-N Selfotel Chemical compound OC(=O)[C@@H]1C[C@H](CP(O)(O)=O)CCN1 LPMRCCNDNGONCD-RITPCOANSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010043220 Temporomandibular joint syndrome Diseases 0.000 description 1
208000009979 Traumatic Amputation Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046798 Uterine leiomyoma Diseases 0.000 description 1
208000021017 Weight Gain Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
MGVGMXLGOKTYKP-ZFOBEOMCSA-N acetic acid;(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC(O)=O.C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 MGVGMXLGOKTYKP-ZFOBEOMCSA-N 0.000 description 1
238000007259 addition reaction Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
230000003356 anti-rheumatic effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229940125708 antidiabetic agent Drugs 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940124433 antimigraine drug Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
229960005207 auranofin Drugs 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
210000003445 biliary tract Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
229960001736 buprenorphine Drugs 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
208000012696 congenital leptin deficiency Diseases 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
DFLRGCFWSRELEL-UHFFFAOYSA-N cyclobut-2-en-1-one Chemical compound O=C1CC=C1 DFLRGCFWSRELEL-UHFFFAOYSA-N 0.000 description 1
CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical class C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
PAFZNILMFXTMIY-UHFFFAOYSA-O cyclohexylammonium Chemical compound [NH3+]C1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-O 0.000 description 1
150000001941 cyclopentenes Chemical class 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
239000007950 delayed release tablet Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
229960003314 deracoxib Drugs 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
229960004515 diclofenac potassium Drugs 0.000 description 1
KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
229960000616 diflunisal Drugs 0.000 description 1
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
XXBDWLFCJWSEKW-UHFFFAOYSA-N dimethylbenzylamine Chemical compound CN(C)CC1=CC=CC=C1 XXBDWLFCJWSEKW-UHFFFAOYSA-N 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
238000002224 dissection Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
239000000975 dye Substances 0.000 description 1
201000003511 ectopic pregnancy Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
201000009274 endometriosis of uterus Diseases 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
229960005293 etodolac Drugs 0.000 description 1
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
229960004945 etoricoxib Drugs 0.000 description 1
MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
229960002428 fentanyl Drugs 0.000 description 1
IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
230000006870 function Effects 0.000 description 1
239000004083 gastrointestinal agent Substances 0.000 description 1
229940125695 gastrointestinal agent Drugs 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
239000003825 glutamate receptor antagonist Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
150000002344 gold compounds Chemical class 0.000 description 1
229940015045 gold sodium thiomalate Drugs 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
GLUUGHFHXGJENI-UHFFFAOYSA-O hydron piperazine Chemical compound [H+].C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-O 0.000 description 1
229960002927 hydroxychloroquine sulfate Drugs 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
239000002555 ionophore Substances 0.000 description 1
230000000236 ionophoric effect Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
XVQUOJBERHHONY-UHFFFAOYSA-N isometheptene Chemical compound CNC(C)CCC=C(C)C XVQUOJBERHHONY-UHFFFAOYSA-N 0.000 description 1
229960003046 isometheptene Drugs 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000013016 learning Effects 0.000 description 1
229960000681 leflunomide Drugs 0.000 description 1
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
201000010260 leiomyoma Diseases 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
229960001929 meloxicam Drugs 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960001293 methylprednisolone acetate Drugs 0.000 description 1
229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
208000015994 miscarriage Diseases 0.000 description 1
208000001022 morbid obesity Diseases 0.000 description 1
YNAVUWVOSKDBBP-UHFFFAOYSA-O morpholinium Chemical compound [H+].C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-O 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960004270 nabumetone Drugs 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
229960000965 nimesulide Drugs 0.000 description 1
HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
230000001473 noxious effect Effects 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
229940100688 oral solution Drugs 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
229960002739 oxaprozin Drugs 0.000 description 1
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
229960002085 oxycodone Drugs 0.000 description 1
239000012057 packaged powder Substances 0.000 description 1
230000037324 pain perception Effects 0.000 description 1
229940124641 pain reliever Drugs 0.000 description 1
230000001734 parasympathetic effect Effects 0.000 description 1
210000001002 parasympathetic nervous system Anatomy 0.000 description 1
229960004662 parecoxib Drugs 0.000 description 1
TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
229960000482 pethidine Drugs 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
229960002943 prednisolone sodium phosphate Drugs 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
108091006082 receptor inhibitors Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
229950009825 selfotel Drugs 0.000 description 1
230000020341 sensory perception of pain Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
235000013555 soy sauce Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
208000005198 spinal stenosis Diseases 0.000 description 1
208000000995 spontaneous abortion Diseases 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
229960004739 sufentanil Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
229960001940 sulfasalazine Drugs 0.000 description 1
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003356 suture material Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
230000003956 synaptic plasticity Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
210000001738 temporomandibular joint Anatomy 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000000542 thalamic effect Effects 0.000 description 1
125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-O triethanolammonium Chemical compound OCC[NH+](CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-O 0.000 description 1
ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
DRDCQJADRSJFFD-UHFFFAOYSA-N tris-hydroxymethyl-methyl-ammonium Chemical compound OC[N+](C)(CO)CO DRDCQJADRSJFFD-UHFFFAOYSA-N 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
229960002004 valdecoxib Drugs 0.000 description 1
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
208000037911 visceral disease Diseases 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

UA20040503402A 2001-10-10 2002-09-10 Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain UA78529C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32824501P	2001-10-10	2001-10-10
PCT/US2002/032252 WO2003031416A2 (en)	2001-10-10	2002-10-09	[[2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain

Publications (1)

Publication Number	Publication Date
UA78529C2 true UA78529C2 (en)	2007-04-10

Family

ID=23280159

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040503402A UA78529C2 (en)	2001-10-10	2002-09-10	Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain

Country Status (27)

Country	Link
US (2)	US7098200B2 (de)
EP (1)	EP1434588B1 (de)
JP (1)	JP4350512B2 (de)
KR (1)	KR100922703B1 (de)
CN (1)	CN100448449C (de)
AR (1)	AR036764A1 (de)
AT (1)	ATE515266T1 (de)
AU (1)	AU2009201746A1 (de)
BR (1)	BR0213237A (de)
CA (1)	CA2461348C (de)
CY (1)	CY1111909T1 (de)
DK (1)	DK1434588T3 (de)
EA (1)	EA009993B1 (de)
ES (1)	ES2367356T3 (de)
HK (1)	HK1064609A1 (de)
HU (1)	HUP0401773A3 (de)
IL (2)	IL161275A0 (de)
MX (1)	MXPA04003354A (de)
NO (1)	NO20041378L (de)
NZ (1)	NZ532159A (de)
PL (1)	PL368863A1 (de)
PT (1)	PT1434588E (de)
SI (1)	SI1434588T1 (de)
TW (1)	TWI321472B (de)
UA (1)	UA78529C2 (de)
WO (1)	WO2003031416A2 (de)
ZA (1)	ZA200403406B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3241550T3 (da)	2002-11-22	2020-08-24	Gruenenthal Gmbh	Anvendelse af (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol til behandling af inflammatoriske smerter
JP2006522834A (ja) *	2003-04-09	2006-10-05	ワイス	［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸および誘導体の鼻腔内投与用医薬組成物およびその使用法
PL1611144T3 (pl) *	2003-04-09	2011-03-31	Wyeth Llc	Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA)
US20050142192A1 (en) *	2003-10-15	2005-06-30	Wyeth	Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
TW200514775A (en)	2003-10-22	2005-05-01	Wyeth Corp	Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
BRPI0516549A (pt) *	2004-10-08	2008-09-09	Wyeth Corp	derivados de ácido [2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil ]fosfÈnico e métodos para sua fabricação
EP2195031A1 (de) *	2007-08-27	2010-06-16	Wyeth a Corporation of the State of Delaware	Zusammensetzungen und verfahren unter einsatz von nmda-antagonisten zur herbeiführung einer eine anästhesie überflüssig machenden wirkung
AU2010213580A1 (en)	2009-02-13	2011-09-08	Allergan, Inc.	Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
MX2011009716A (es)	2009-03-19	2011-10-17	Wyeth Llc	Metodos para la preparacion de acido [2-(8,9-dioxo)-2,6-diazabicic lo[5.2.0]non-1(7)-en-2-il)etil]fosfonico y precursores de este.
EP2782569A1 (de)	2011-11-21	2014-10-01	Allergan, Inc.	Pharmazeutische zusammensetzungen mit 4-[1-(2,3-dimethylphenyl-)ethyl-]3h-imidazolderivaten zur behandlung von netzhauterkrankungen
US10292989B2 (en)	2014-03-28	2019-05-21	University Of Virginia Patent Foundation	General anesthetics that are not neurotoxic

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5168103A (en) *	1991-01-22	1992-12-01	American Home Products Corporation	[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5124319A (en) *	1991-10-11	1992-06-23	American Home Products Corporation	Benzimidazole phosphono-amino acids
DK124393D0 (da)	1993-11-03	1993-11-03	Lundbeck & Co As H	Compounds
AT400440B (de) *	1993-12-06	1995-12-27	Vianova Kunstharz Ag	Verfahren zur herstellung von wasserverdünnbaren lackbindemitteln und deren verwendung
TW427904B (en) *	1995-12-07	2001-04-01	American Home Prod	Neuroprotective agents
UA52698C2 (uk) *	1996-10-04	2003-01-15	Х. Луннбек А/С	Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі
IL163574A (en)	1997-08-01	2008-06-05	Wyeth Corp	Process for the preparation of D. ester of N - [3 - (Butylcoscarbonylamino tart) - profile] - 2 - Aminoethyl phosphonic acid
US5990307A (en) *	1997-08-01	1999-11-23	American Home Products Corporation	Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid
US6362371B1 (en)	1998-06-08	2002-03-26	Advanced Medicine, Inc.	β2- adrenergic receptor agonists
US6225343B1 (en) *	1999-06-16	2001-05-01	Nastech Pharmaceutical Company, Inc.	Compositions and methods comprising morphine gluconate
US20030158254A1 (en)	2002-01-24	2003-08-21	Xenoport, Inc.	Engineering absorption of therapeutic compounds via colonic transporters
US20040082543A1 (en) *	2002-10-29	2004-04-29	Pharmacia Corporation	Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain

2002
- 2002-09-10 UA UA20040503402A patent/UA78529C2/uk unknown
- 2002-10-08 AR ARP020103791A patent/AR036764A1/es unknown
- 2002-10-09 MX MXPA04003354A patent/MXPA04003354A/es active IP Right Grant
- 2002-10-09 IL IL16127502A patent/IL161275A0/xx unknown
- 2002-10-09 CA CA2461348A patent/CA2461348C/en not_active Expired - Fee Related
- 2002-10-09 PT PT02789180T patent/PT1434588E/pt unknown
- 2002-10-09 BR BR0213237-0A patent/BR0213237A/pt not_active Application Discontinuation
- 2002-10-09 TW TW091123270A patent/TWI321472B/zh not_active IP Right Cessation
- 2002-10-09 SI SI200230959T patent/SI1434588T1/sl unknown
- 2002-10-09 PL PL02368863A patent/PL368863A1/xx not_active IP Right Cessation
- 2002-10-09 DK DK02789180.3T patent/DK1434588T3/da active
- 2002-10-09 AT AT02789180T patent/ATE515266T1/de active
- 2002-10-09 JP JP2003534400A patent/JP4350512B2/ja not_active Expired - Fee Related
- 2002-10-09 KR KR1020047005298A patent/KR100922703B1/ko not_active IP Right Cessation
- 2002-10-09 CN CNB028202430A patent/CN100448449C/zh not_active Expired - Fee Related
- 2002-10-09 HU HU0401773A patent/HUP0401773A3/hu unknown
- 2002-10-09 US US10/267,159 patent/US7098200B2/en not_active Expired - Fee Related
- 2002-10-09 EP EP02789180A patent/EP1434588B1/de not_active Expired - Lifetime
- 2002-10-09 NZ NZ532159A patent/NZ532159A/en not_active IP Right Cessation
- 2002-10-09 WO PCT/US2002/032252 patent/WO2003031416A2/en active Application Filing
- 2002-10-09 EA EA200400523A patent/EA009993B1/ru not_active IP Right Cessation
- 2002-10-09 ES ES02789180T patent/ES2367356T3/es not_active Expired - Lifetime
2004
- 2004-04-02 NO NO20041378A patent/NO20041378L/no unknown
- 2004-04-04 IL IL161275A patent/IL161275A/en not_active IP Right Cessation
- 2004-05-05 ZA ZA200403406A patent/ZA200403406B/en unknown
- 2004-10-05 HK HK04107633.4A patent/HK1064609A1/xx not_active IP Right Cessation
2006
- 2006-05-12 US US11/433,737 patent/US7759346B2/en not_active Expired - Fee Related
2009
- 2009-05-01 AU AU2009201746A patent/AU2009201746A1/en not_active Ceased
2011
- 2011-08-02 CY CY20111100744T patent/CY1111909T1/el unknown

Also Published As

Publication number	Publication date
US7759346B2 (en)	2010-07-20
EP1434588B1 (de)	2011-07-06
IL161275A (en)	2009-09-01
JP4350512B2 (ja)	2009-10-21
EA009993B1 (ru)	2008-06-30
PT1434588E (pt)	2011-09-05
MXPA04003354A (es)	2004-09-28
PL368863A1 (en)	2005-04-04
CA2461348A1 (en)	2003-04-17
CN100448449C (zh)	2009-01-07
AR036764A1 (es)	2004-09-29
US20030114444A1 (en)	2003-06-19
HUP0401773A2 (hu)	2005-01-28
ATE515266T1 (de)	2011-07-15
DK1434588T3 (da)	2011-08-15
CY1111909T1 (el)	2015-11-04
WO2003031416A2 (en)	2003-04-17
EA200400523A1 (ru)	2004-08-26
US20060205696A1 (en)	2006-09-14
HUP0401773A3 (en)	2005-06-28
NZ532159A (en)	2006-02-24
AU2009201746A1 (en)	2009-05-28
US7098200B2 (en)	2006-08-29
ZA200403406B (en)	2007-04-25
HK1064609A1 (en)	2005-02-04
CN1568189A (zh)	2005-01-19
WO2003031416A3 (en)	2003-08-14
SI1434588T1 (sl)	2011-10-28
EP1434588A2 (de)	2004-07-07
KR20050034604A (ko)	2005-04-14
TWI321472B (en)	2010-03-11
ES2367356T3 (es)	2011-11-02
IL161275A0 (en)	2004-09-27
CA2461348C (en)	2011-02-15
KR100922703B1 (ko)	2009-10-22
JP2005508950A (ja)	2005-04-07
BR0213237A (pt)	2004-09-28
NO20041378L (no)	2004-05-28

Publication	Publication Date	Title
US7759346B2 (en)	2010-07-20	[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain
Mercadante et al.	2001	Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness
US20070225277A1 (en)	2007-09-27	Treatment of pain
US20010036943A1 (en)	2001-11-01	Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20060258713A1 (en)	2006-11-16	Treatment of pain
CN111065390A (zh)	2020-04-24	Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途
US6107330A (en)	2000-08-22	Inhibitor for narcotic analgesic dependence/resistance acquisition
JPWO2005099696A1 (ja)	2008-03-06	アセチルコリンエステラーゼ阻害薬と５−置換−３−オキサジアゾリル−１，６−ナフチリジン−２（１ｈ）−オン誘導体とを組み合わせてなる医薬
KR101614966B1 (ko)	2016-04-22	동통 치료약
CN111050800B (zh)	2023-04-04	血清素3受体激动剂对疼痛的治疗
AU2002353792A1 (en)	2003-04-22	((2-(amino-3,4-dioxo-1cyclobuten-1-YL)amino)alkyl)-acid derivatives for the treatment of pain
WO2006115302A1 (ja)	2006-11-02	神経因性疼痛治療剤
WO2005094797A2 (en)	2005-10-13	Use of ampa-receptor antagonists for treating dementia
WO2005049039A1 (en)	2005-06-02	Combinations comprising ampa receptors antagonists for the treatment of affective and attention deficit disorders
CN101355947A (zh)	2009-01-28	用于治疗的噻唑并嘧啶类
TW201103546A (en)	2011-02-01	New use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives